niclosamide sodium salt

Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].

Signaling Pathways >> Stem Cell/Wnt >> STAT

Research Areas >> Cancer

Research Areas >> Infection

Signaling Pathways >> JAK/STAT Signaling >> STAT

Niclosamide sodium (0.6 nM-46 µM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells[3]. Niclosamide sodium (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells[4]. Niclosamide sodium (10 μM) treatment inhibits virus replication in Vero E6 cells[5]. Cell Viability Assay[3] Cell Line: BD140A, SW-13 and NCI-H295R cells Concentration: 0.6 nM-46 µM Incubation Time: Result: Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively. Cell Viability Assay[4] Cell Line: Hela cells Concentration: 0.05-5 μM Incubation Time: 24 hours Result: Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM. Western Blot Analysis[5] Cell Line: Vero E6 cells Concentration: 10 μM Incubation Time: 2 days Result: Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.

Niclosamide sodium (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo[3]. Animal Model: Nu+/Nu+ mice injected with NCI-H295R cells[3] Dosage: 100 mg/kg, 200 mg/kg Administration: Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks Result: Showed a 60%-80% inhibition in tumor growth, as compared to the control group.

[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95.

[2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.

[3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66.

[4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9.

[5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.